A validated assay for measuring doxorubicin in biological fluids and tissues in an isolated lung perfusion model:: matrix effect and heparin interference strongly influence doxorubicin measurements

被引:35
作者
Kümmerle, A
Krueger, T
Dusmet, M
Vallet, C
Pan, Y
Ris, HB
Decosterd, LA [1 ]
机构
[1] CHUV, Lab BH 18 218, Div Clin Pharmacol, NL-1011 NH Amsterdam, Netherlands
[2] CHU Vaudois, Serv Chirurg Thorac & Vasc, Lausanne, Switzerland
关键词
doxorubicin; heparin interference; lung perfusion model; fluids;
D O I
10.1016/S0731-7085(03)00300-5
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Doxorubicin is an antineoplasic agent active against sarcoma pulmonary metastasis, but its clinical use is hampered by its myelotoxicity and its cumulative cardiotoxicity, when administered systemically. This limitation may be circumvented using the isolated lung perfusion (ILP) approach, wherein a therapeutic agent is infused locoregionally after vascular isolation of the lung. The influence of the mode of infusion (anterograde (AG): through the pulmonary artery (PA); retrograde (RG): through the pulmonary vein (PV)) on doxorubicin pharmacokinetics and lung distribution was unknown. Therefore, a simple, rapid and sensitive high-performance liquid chromatography method has been developed to quantify doxorubicin in four different biological matrices (infusion effluent, serum, tissues with low or high levels of doxorubicin). The related compound daunorubicin was used as internal standard (I.S.). Following a single-step protein precipitation of 500 mul samples with 250 mul acetone and 50 mul zinc sulfate 70% aqueous solution, the obtained supernatant was evaporated to dryness at 60 degreesC for exactly 45 min under a stream of nitrogen and the solid residue was solubilized in 200 mul of purified water. A 100 mul-volume was subjected to HPLC analysis onto a Nucleosil 100-5 mum C18 AB column equipped with a guard column (Nucleosil 100-5 mum C6H5 (phenyl) end-capped) using a gradient elution of acetonitrile and 1-heptanesulfonic acid 0.2% pH 4: 15/85 at 0 min --> 50/50 at 20 min --> 100/0 at 22 min --> 15/85 at 24 min --> 15/85 at 26 min, delivered at 1 ml/min. The analytes were detected by fluorescence detection with excitation and emission wavelength set at 480 and 550 nm, respectively. The calibration curves were linear over the range of 2-1000 ng/ml for effluent and plasma matrices, and 0.1 mug/g-750 mug/g for tissues matrices. The method is precise with inter-day and intra-day relative standard deviation within 0.5 and 6.7% and accurate with inter-day and intra-day deviations between -5.4 and +7.7%. The in vitro stability in all matrices and in processed samples has been studied at -80 degreesC for 1 month, and at 4 degreesC for 48 h, respectively. During initial studies, heparin used as anticoagulant was found to profoundly influence the measurements of doxorubicin in effluents collected from animals under ILP. Moreover, the strong matrix effect observed with tissues samples indicate that it is mandatory to prepare doxorubicin calibration standard samples in biological matrices which would reflect at best the composition of samples to be analyzed. This method was successfully applied in animal studies for the analysis of effluent, serum and tissue samples collected from pigs and rats undergoing ILP. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:475 / 494
页数:20
相关论文
共 43 条
  • [1] Isolated lung perfusion with doxorubicin prolongs survival in a rodent model of pulmonary metastases
    Abolhoda, A
    Brooks, A
    Nawata, S
    Kaneda, Y
    Cheng, HM
    Burt, ME
    [J]. ANNALS OF THORACIC SURGERY, 1997, 64 (01) : 181 - 184
  • [2] High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues
    Alvarez-Cedrón, L
    Sayalero, ML
    Lanao, JM
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1999, 721 (02): : 271 - 278
  • [3] A SENSITIVE AND SIMPLE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF DOXORUBICIN AND ITS METABOLITES IN PLASMA
    ANDERSEN, A
    WARREN, DJ
    SLORDAL, L
    [J]. THERAPEUTIC DRUG MONITORING, 1993, 15 (05) : 455 - 461
  • [4] AOYAMA T, 1987, CHEM PHARM BULL, V35, P808
  • [5] ADRIAMYCIN, 14-HYDROXYDAUNOMYCIN, A NEW ANTITUMOR ANTIBIOTIC FROM S-PEUCETIUS VAR CAESIUS
    ARCAMONE, F
    CASSINEL.G
    FANTINI, G
    GREIN, A
    OREZZI, P
    POL, C
    SPALLA, C
    [J]. BIOTECHNOLOGY AND BIOENGINEERING, 1969, 11 (06) : 1101 - &
  • [6] Isolated lung perfusion for patients with unresectable metastases from sarcoma: A Phase I trial
    Burt, ME
    Liu, D
    Abolhoda, A
    Ross, HM
    Kaneda, Y
    Jara, E
    Casper, ES
    Ginsberg, RJ
    Brennan, MF
    [J]. ANNALS OF THORACIC SURGERY, 2000, 69 (05) : 1542 - 1549
  • [7] High-performance liquid chromatographic methods for the determination of topoisomerase II inhibitors
    Chen, CL
    Thoen, KK
    Uckun, FM
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2001, 764 (1-2): : 81 - 119
  • [8] ANTIHEPARIN ACTIVITY OF ADRIAMYCIN
    COFRANCESCO, E
    VIGO, A
    POGLIANI, E
    [J]. THROMBOSIS RESEARCH, 1980, 18 (05) : 743 - 746
  • [9] COHEN MH, 1985, CANCER TREAT REP, V69, P1325
  • [10] COLOMBO T, 1981, BIOMEDICINE, V34, P124